Navigation Links
VCU Massey Cancer Center awarded $2.4 million grant from Virginia Tobacco Commission
Date:10/28/2010

Virginia Commonwealth University Massey Cancer Center recently was awarded a two-year, $2.4 million grant from the Virginia Tobacco Indemnification and Community Revitalization Commission (Tobacco Commission) to expand the breadth of the center's community involvement and to grow its state-of-the-art clinical research and cancer specialist delivery system. That delivery system is already in place in communities across Virginia, such as in the Lynchburg, Fredericksburg and Newport News areas.

The award builds upon a previous grant of $1 million that the Tobacco Commission awarded to VCU Massey in 2008. The first grant supported Massey in bringing its nationally recognized cancer clinical trials and prevention and control research to Southside and Southwest Virginia through a new cancer research community outreach program.

The latest grant will support VCU Massey in expanding that work. Specifically, it provides funding for the extension of Massey's cancer prevention and control and epidemiologic research initiatives into the Virginia Southside and Southwest tobacco counties. It also helps fund the expansion of a health information literacy program for the citizens of those communities, as well as the implementation of a comprehensive cancer needs assessment to identify gaps in cancer services and then to mobilize resources to meet the identified cancer needs of those counties.

"The ultimate goal of our community outreach work is to reduce the suffering and death from cancer for citizens throughout the Commonwealth," said Gordon D. Ginder, M.D., Director of VCU Massey Cancer Center. "We are grateful for the Tobacco Commission's support of these efforts, and we are pleased that through their partnership, we can bring Massey's experts and top-notch cancer care to Virginia's predominately rural areas, where we are most needed because cancer mortality rates are higher there than elsewhere in the country."

"We are pleased to assist VCU Massey Cancer Center in its research program," said Tobacco Commission Chairman and Virginia Delegate Terry Kilgore. "The Tobacco Commission believes it will be a great asset to the Commonwealth of Virginia and its citizens."

Experts estimate that this year more than 14,000 Virginians will die of cancer and approximately 36,000 new cancer cases will be diagnosed in the state. The number is expected to double to 70,000 by 2040.

Cancer's economic impact in Virginia is estimated at $2.6 billion in lifetime productivity. A 1 percent reduction in cancer mortality rates would reduce health care costs by millions of dollars annually. And early detection and prevention practices can save millions of dollars in Medicare and Medicaid expenses if effectively implemented.

The work funded by this grant is aimed directly at resolving these issues to increase cancer prevention and early detection, and decrease cancer mortality rates, throughout the state of Virginia. "VCU Massey Cancer Center is proud to lead that effort," Ginder said.


'/>"/>

Contact: Jenny Owen
jrowen2@vcu.edu
804-628-2111
Virginia Commonwealth University
Source:Eurekalert

Related medicine news :

1. Key leukemia defense mechanism discovered by VCU Massey Cancer Center
2. VCU Massey research finds new link between inflammation and cancer
3. Study Finds Green Tea Offers No Protection From Breast Cancer
4. New Drug Shows Promise Against Certain Lung Cancers
5. Many male cancer patients are missing out on sperm banking
6. Smart drug targets new mutation, dramatically shrinks aggressive sarcoma and lung cancer
7. Tumor suppressor acts as oncogene in some cancers, say Mayo Clinic researchers
8. Pancreatic Cancer Surprisingly Slow to Arise: Study
9. Surprise finding: Pancreatic cancers progress to lethal stage slowly
10. Forces for cancer spread: Genomic instability and evolutionary selection
11. Certain cancer therapies success depends on presence of immune cell, Stanford study shows in mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... An August 2 article ... obtaining plastic surgery, largely influenced by the growing popularity of “pretty boys” in both ... notes that standards of male appearance are changing not only in the Asian nation, ...
(Date:8/17/2017)... ... 2017 , ... Pot Valet is a leading provider of premium medical-grade cannabis ... state, and soon, every state in the country, the company offers patients safe, legal, ... altogether. , According to Pot Valet, all California patients have the legal ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... A recent ... to the biopharmaceutical industry in 2016 cited deficiencies in data integrity. The FDA outlines ... Part 11 ruling. , Presented as part of the Beckman Coulter Life ...
(Date:8/16/2017)... Los Angeles, California (PRWEB) , ... August 16, 2017 , ... An August 3rd ... patients that was the subject of a report in JAMA (the Journal of the American ... (BMIs) above 50 were able to achieve BMIs under 30, when compared to patients with ...
(Date:8/16/2017)... ... August 16, 2017 , ... For the second ... England student to educate the public on the impact of concussions. Brooke Mills, ... first-ever National Concussion Awareness Day. , Brooke is working diligently is to raise ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... quarter ended June 30, 2017, and updated its financial ... For the fiscal third quarter, Hill-Rom reported ... per diluted share in the prior-year period. These results ... per diluted share primarily related to the non-cash write-down ...
(Date:7/27/2017)... Pharmaceutical Services, Inc. (NYSE: WST ) today ... updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record ... at constant currency (organic) grew by 3.9%. ... $0.60 in the prior-year quarter. Second-quarter 2017 adjusted diluted ...
(Date:7/26/2017)... July 26, 2017 Sancilio Pharmaceuticals Company, Inc. ... clinical trial evaluating Altemia TM , an oral therapy ... Sickle Cell Disease (SCD). The SCOT Trial, is a ... and safety of Altemia TM in pediatric patients ... US IND 125274. ...
Breaking Medicine Technology: